Excerpt from Angiolymphoid Hyperplasia With EosinophiliaSynonyms, Key Words, and Related Terms: epithelioid hemangioma, histiocytoid hemangioma, pseudopyogenic granuloma, papular angioplasia, inflammatory angiomatous nodule, inflammatory arteriovenous hemangioma, intravenous atypical proliferation. Please click here to view the full topic text: Angiolymphoid Hyperplasia With EosinophiliaBackgroundAngiolymphoid hyperplasia with eosinophilia (ALHE) is an uncommon idiopathic condition that manifests in adults as isolated or grouped papules, plaques, or nodules in the skin of the head and neck. Most patients present with lesions in the periauricular region, forehead, or scalp. Rare sites of involvement include the hands, shoulders, breasts, penis, oral mucosa, and orbit. A distinct pathologic entity, ALHE is marked by a proliferation of blood vessels with distinctive large endothelial cells. These blood vessels are accompanied by a characteristic inflammatory infiltrate that includes eosinophils. The lesion is benign but may be persistent and is difficult to eradicate. Whether ALHE represents a benign neoplasm or an unusual reaction to varied stimuli, including trauma, remains unclear. While ALHE shows some similarity to Kimura disease, it is a separate entity. While ALHE lesions are superficial, Kimura disease involves deeper tissues such as lymph nodes, salivary glands, and the subcutis. However, a recent report describes ALHE involving the nail bed and underlying bone. PathophysiologyAlthough ALHE may be a benign tumor, numerous factors suggest that it is an unusual reactive process. Approximately half the patients have multifocal lesions that are grouped anatomically. ALHE has occurred following various forms of trauma or infection. Histologically, most cases of ALHE show damaged and/or tortuous arteries and veins at the base of the lesion, suggesting that arteriovenous shunting may play a role in the pathogenesis. Hyperestrogenemia (eg, in pregnancy, with oral contraceptive use) may foster lesion growth. Additionally, the distinctive inflammatory infiltrate in ALHE appears to be an intrinsic (not secondary) component of the lesion. Approximately 20% of patients have blood eosinophilia. FrequencyUnited StatesFrequency in the United States is unknown. ALHE is uncommon but not rare. InternationalAlthough frequency is unknown, cases have been reported worldwide. ALHE is uncommon but not rare; it may be more common in Japan than in other countries. Mortality/MorbidityALHE can persist for years, but serious complications (eg, malignant transformation) do not occur. A few cases of nephropathy have been reported in patients with ALHE; however, the association is not strong. This is in contrast to the related entity, Kimura disease, for which the association with nephrotic syndrome is strong. RaceALHE is seen most commonly in Asians, followed by whites. Although less common, blacks can develop ALHE. SexALHE is slightly more common in females; however, a male predominance has been noted in selected Asian studies. AgeALHE presents most commonly in patients aged 20-50 years, with mean onset of 30-33 years. This condition is rare in elderly patients and in the non-Asian pediatric population. Please click here to view the full topic text: Angiolymphoid Hyperplasia With Eosinophilia |
| About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers |
|
|
|||
|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |